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InvasionHigh activity of GLI family zinc ﬁnger protein 2 (GLI2) promotes tumor progression. Removal of the repressor
domain at the N terminus (GLI2ΔN) by recombinant methods converts GLI2 into a powerful transcriptional
activator. However, molecular mechanisms leading to the formation of GLI2ΔN activator proteins have not
been established. Hereinwe report for the ﬁrst time that the functional activities of GLI2 are parted into different
protein isoforms by alternative promoter usage, selection of alternative splicing, transcription initiation and
termination sites. Functional studies using melanoma cells revealed that transcriptional regulation of GLI2 is
TGFbeta-dependent and supports the predominant production of GLI2ΔN and C-terminally truncated GLI2
(GLI2ΔC) isoforms in cells with high migratory and invasive phenotype. Taken together, these results highlight
the role of transcription and RNA processing as major processes in the regulation of GLI2 activity with severe
impacts in cancer development.
© Elsevier B.V. All rights reserved.20151. Introduction
Glioma-associated oncogene proteins 1, 2, and 3 (GLI1, GLI2, and
GLI3) belong to the family of Krüppel-like transcription factors with
C2H2-Zn ﬁnger DNA-binding domains. GLI proteins are the main
effectors of the Sonic Hedgehog (Hh) pathway that is important during
embryonic development and in adult [1,2]. All three GLI proteins con-
tribute to tumor progression by stimulating cell cycle progression,
inhibiting apoptosis [2–4] and promoting tumor cell invasion and
metastasis [5–8].
GLI proteins act as transcription activators and repressors depending
on the cellular context. All GLI proteins have C-terminal activation
domains, whereas GLI2 and GLI3 additionally possess an N-terminal re-
pressor domain [9–11]. Previous studies have found that transcriptional
activity of GLI2/3 proteins is controlled via regulated proteolytic pro-
cessing generating C-terminally truncated repressors (GLI2ΔC and
GLI3ΔC). While Hh signaling is central to the transcriptional activity of
GLI proteins, numerous studies suggest regulation of expression and ac-
tivation of GLI2 by signaling pathways other than Hh [12,13]. Recent
studies have established the role of TGFbeta signaling in non-
canonical activation of GLI2 in melanoma cells with metastatic
phenotype [14,15].allinn 12618, Estonia.Extensive studies of GLI proteins have lasted over 15 years. However,
understanding the formation of GLI2 activator proteins has remained
vague. Early studies showed that unlike the mouse Gli2, the human
counterpart does not contain an N-terminal repressor domain
(GLI2ΔN) and acts as a transcriptional activatorwith amolecularweight
of 133 kDa [16]. The structure of human GLI2was revisited with the de-
scription of transcripts encoding the 162 kDa canonical GLI2 protein
which is structurally similar to the mouse Gli2 with an N-terminal re-
pressor domain [9]. With these ﬁndings it became obvious that the re-
moval of the N-terminal repressor domain is indispensable for the full
exposure of the activator potential of human GLI2 [9,11,17]. Since
then, most of the studies on GLI2 function have used recombinant
GLI2ΔN isoforms [18–20]. However, the mechanisms for production of
GLI2ΔNprotein isoforms have remained unknown. Furthermore, detec-
tion of endogenous GLI2 proteins with commercially available antibod-
ies has been challenging as the latter could barely identify the canonical
form of GLI2 protein of 168 kDa. Instead, isoforms of GLI2 with a weight
of 133 kDa andwith an unknownmolecular originwere predominantly
detected [21–23].
Recently it has been shown thatGLI1 is subjected to alternative splic-
ing that leads to the synthesis of the N-terminally truncated isoforms
GLI1ΔN [24] and tGLI1 [25]. Compared to the canonical form of GLI1,
these isoforms show tissue-speciﬁc patterns of expression and function
[24–26]. Previous studies of GLI2 have described that the usage of 5′
exons in GLI2mRNAs encoding the repressor domain is different in can-
cer cells [16,17]. In the current study we describe the identiﬁcation of
four mutually exclusive 5′ non-coding exons of human GLI2 with
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ed in normal versusmalignant tissues. Because of this, we have revisited
the human GLI2 gene structure. In addition, we analyzed the expression
of GLI2mRNAs across normal tissues and in cancer, explored the use of
transcription start/termination sites and dissected the activity of differ-
ent promoters in producing functionally distinct isoforms. Finally, we
discovered that migrating cells predominantly expressed transcription
activator GLI2ΔN and GLI2ΔC isoforms with molecular weights of
133 kDa and 48 kDa respectively. Furthermore, the production of
these isoformswas enhanced by TGFbeta1 signaling. These data strong-
ly argue for the critical role of signal-induced post-transcriptional pro-
cessing of GLI2 in executing cell-speciﬁc activity and governing tumor
progression and invasion.
2. Materials and methods
2.1. Ethics statement
Human tissues for RNA analysis and skin for primary dermal
ﬁbroblast isolation were obtained from the North-Estonian Regional
Hospital, Tallinn, Estonia, with the approval from the local ethics
committee (license no. 2234, date of issue 09.12.2010).
2.2. Cell culture
Human cancer cells (ATCC) and primary dermal ﬁbroblasts were
grown in DMEM [27] containing 10% FBS [27], 1 mg/ml penicillin [27]
and 0.1 mg/ml streptomycin [27] at 37 °C in 5% CO2. All studies were
performed at least in three independent experiments run in triplicates.
2.3. Gene structure analysis
Genomic sequence of the GLI2 gene was retrieved from GenBank
(accession number NM_005270.4). To analyze exon/intron boundaries
of the GLI2 gene, the sequences of PCR products were compared with
genome sequences using The Human Genome Browser tool at UCSC
(version GRCh37, http://genome.ucsc.edu/). Newly described se-
quences of GLI2 were submitted to GenBank — http://www.ncbi.nlm.
nih.gov.
2.4. RNA extraction, RT-PCR and qPCR
Commercial RNA samples extracted from primary colon carcinoma
(clinical stages I–IV and tumor grades 1–3, patient age range 25–83
years, BioChain Institute, Inc.), primary breast carcinoma (clinical stages
I–IV and tumor grades 1–3, patient age range 25–83 years; BioChain
Institute, Inc.) and primary melanoma (clinical information unknown,
patient age range 42–83 years; BioChain Institute, Inc.) were used for
analysis.
Total RNA from human cells was isolated using TRIzol® Reagent
(Invitrogen) and total RNA from human tissues was isolated using
RNAWiz (Ambion) as recommended by the manufacturer. One micro-
gram of RNA was reverse transcribed into cDNA using SuperScript III
ﬁrst strand cDNA synthesis kit (Invitrogen) according to the
manufacturer's instructions. The resulting cDNAs were used as tem-
plates for subsequent RT-PCR and qPCR reactions. RT-PCR was carried
out by using HotFire Pol® DNA polymerase (Solis Biodyne), 25–45 am-
pliﬁcation cycles and an annealing temperature of 58 °C. Ampliﬁcation
of the housekeeping gene GAPDH was performed for 25 cycles using
Fire Pol® DNA polymerase (Solis Biodyne) and used as an internal con-
trol. The nucleotide sequences of primers are given in Table S1.
Resulting PCR products were veriﬁed by sequencing using the services
of GATC Biotech AG (Germany). qPCR was carried out using LighCycler
480 SYBR Green I Master kit (Roche) system, 45 ampliﬁcation cycles
and an annealing temperature of 60 °C using a LightCycler 480 II
(Roche)machine and LightCycler 480 SW1.5 (Roche) software. Expres-
sion of RPLP0 (ribosomal protein, large p0) mRNA was used as aninternal control for normalization of target gene expression. The nucle-
otide sequences of primers and the sizes of amplicons are given in
Table S1. The results were analyzed using the 2−ΔΔCT method [28].
Three parallels of a single samplewere used to calculatemean and stan-
dard deviation values. Statistical values were calculated by using
Student's t-test (* — p b 0,05, ** — p b 0005, *** — p b 0001).2.5. Rapid ampliﬁcation of cDNA ends (RACE)
5′-RACE and 3′-RACE ampliﬁcations were performed with the 5′-
and 3′-RACE Systems for Rapid Ampliﬁcation of cDNA Ends kit
(Invitrogen) according to the manufacturer's instructions. In 5′-RACE,
ﬁrst-strand cDNAs were generated by reverse transcription of total
RNA from fetal brain and LoVo cells using primers p14 and p16 speciﬁc
to exon V or exon XV of GLI2, respectively (shown in Table S1).
Amplicons were re-ampliﬁed using nested GLI2-speciﬁc primers p15
or p17 (shown in Table S1) and AUAP (Invitrogen). In 3′-RACE, ﬁrst-
strand cDNA was generated by using polyA+ adapter primers
(Invitrogen). The cDNAwas ampliﬁed by PCR using primer p18 speciﬁc
to exon XII of GLI2 (shown in Table S1) and AUAP (Invitrogen). All am-
pliﬁcation reactions were carried out according to the suggested
thermocycler conditions of the RACE protocols (Invitrogen). All nested
PCR productswere cloned in the pCRII-Topo vector (Invitrogen) and an-
alyzed by sequencing (GATC Biotech AG, Germany).2.6. Cloning, transfection and promoter luciferase assay
A586 bp fragment (−541 to+45 bp) of the 5′-region ofGLI2 exon I,
584 bp fragment (−481 to +103 bp) of the 5′-region of exon II, a
714 bp fragment (−442/−584 to +272/+130 bp) of the 5′-region of
exon III and 575 bp fragment (−561 to +14 bp) of the 5′-region of
exon XI were PCR ampliﬁed and subcloned into the luciferase reporter
vector pGL3-luc-egfp (mod. Promega Corp.). All constructs were
veriﬁed by sequencing (GATC Biotech AG) and designated as GLI2-
prom1-luc (P1), GLI2-prom1-luc (P2), GLI2-prom1-luc (P3) and GLI2-
prom6-luc (P4). Reporter plasmids were cotransfected with pGL3-
CMV-FFLuc vector into U373, SkMel-28, MDA-MB 231, WM266-4 and
A375M cells using the Amaxa Cell line 96-well Nucleofector Kit SE
(Lonza) according to the manufacturer's instructions. Control samples
were obtained by transfecting the cells with pGL3-luc-egfp vector. Pro-
moter activity was assayed by the Dual-Glo luciferase reporter assay
system (Promega Corp.), where the Renilla luciferase activity was
used as a control to standardize the transcription efﬁciency. The data
are represented relatively to the pGL3-luc-egfp control vector transfec-
tion efﬁciency. Results represented are the mean values and standard
deviations from at least three independent transfections performed in
triplicates.2.7. Ribonuclease protection assay
For construction of plasmids for probe synthesis, DNA fragments
speciﬁc for the GLI2 exons X to XII and exons XIII to exon XV extension
were ampliﬁed from cDNA template from the A375M cells using a mix
of FirePol (Solis Biodyne) and Pfu (Fermentas) enzymes. PCR products
were cloned into StrataClone pSC-A vector (Stratagen) and veriﬁed by
sequencing. For probe production, the plasmids were linearized with
XhoI and antisense RNA was synthesized using Ambion MAXI Script
T7/T3 kit according to the manufacturer's instructions using 32P-UTP.
RPA was performed as described previously [8,27] using the RPA kit
from Ambion and 40 μg of total RNA of A375M and 2.5 × 105 CPM of
radiolabeled probe. The protected fragments were separated in 5% ac-
rylamide–urea gel, visualized by autoradiography and quantiﬁed with
ImageQuant T4 software (Amersham Biosciences). The housekeeping
gene GAPDHwas used as control.
48 H. Sadam et al. / Biochimica et Biophysica Acta 1862 (2016) 46–552.8. Western blotting
For protein analysis of isoforms, 30 μg of nuclear protein extracts
from A375M cells were prepared by using NE-PER Nuclear and Cyto-
plasmic Extraction Reagents (Thermo Scientiﬁc). For analysis of migrat-
ed and non-migrated A375M melanoma cells, 50 μg of whole cell
extracts were prepared by using RIPA buffer. The resulting extracts
were resolved by 1.5 mm 7% SDS-polyacrylamide gel electrophoresis
and transferred onto PVDF membranes (Amersham). The primary anti-
bodies usedwere: anti-GLI2 (Santa Cruz Biotechnology sc-28674; Santa
Cruz Biotechnology sc-20291; R&D Systems AF3635), anti-LaminB1
(Abcamab16048) and anti-GAPDH (SigmaG8795). The secondary anti-
bodies consisted of HRP-conjugated anti-rabbit, anti-mouse and anti-
goat IgGs from Abcam. The ECL-femto kit (Pierce) was used for detec-
tion of immunoblotted target proteins. ImageJ ver. 1.47 was used for
quantiﬁcation of Western blot results. Average and standard deviation
values were calculated from multiple independent quantiﬁcations of a
single blot.
2.9. Cell treatments and in vitro invasion/migration assay
Melanoma A375M cells were treated with 10 ng/ml TGF-β1
(Peprotech EC) for 24 h, whereupon RNA was extracted and RT-PCR
analysis was performed as described above. Cellular invasion was ana-
lyzed using a transwell migration assay (QCM™ 24-Well Colorimetric
Cell Migration Assay (Millipore)). For ECM synthesis and the following
invasion assay,membraneswere coatedwith 7× 105 primary dermalﬁ-
broblasts. After 24 h growth on the membranes, ﬁbroblasts were lyzed
with hypotonic buffer (10 mM Tris; 1 mM EDTA pH 7.4) and removed.
The upper chamber was seeded with 200,000 melanoma cells per
well. The bottom chamber contained normal medium, including 10%
FBS as the chemoattractant, whereas themedium in the upper chamber
was without FBS. After 20 h of transwell migration, the membrane was
stained with Cell Stain solution (Millipore) according to the
manufacturer's instructions. The population of non-migrated cells in
the upper chamber was removed and subjected to RNA extraction and
RT-PCR analysis or protein extraction and Western blot analysis as de-
scribed above. For measuring the number of cells migrating towards
the chemoattractant, cells on the underside of the membrane were
counted using a Nikon Eclipse 80i digital microscope. The insert with
the remaining population of cells was placed into the Extraction Buffer
(Millipore) and the absorption of the extracted dye was analyzed at
OD value 560 nm for determination of viable cell numbers. The cells
that migrated across the membrane were used for subsequent RNA ex-
traction and PCR analysis or protein extraction andWestern blot analy-
sis as described above. All TGF-β1 treatments and invasion/migration
assays were carried out in triplicates.
3. Results
3.1. Use of alternative transcription start and termination sites creates
diversity in GLI2 transcripts
Our initial aim was to delineate the role of splicing in regulation of
GLI2 activity in different types of cancer. For that we analyzed tissue
samples from primary colon carcinoma (clinical stages I–IV and tumor
grades 1–3, patient age range 25–83 years), primary breast carcinoma
(clinical stages I–IV and tumor grades 1–3, patient age range 25–83
years) and primary melanoma (clinical information unknown, patient
age range 42–83 years) by RT-PCR method. Data analysis revealed a
range of different transcripts of GLI2 of various lengths that were more
abundant in tumors and fetal tissues as compared to adult normal tis-
sues (Fig. 1A). Number of novel alternative splice variants (ASV) was
found that included four novel exons: one located in the 5′ region
(splice variants v30–v38) and three in the middle of the coding region
(splice variants v11, v18, v26, v27, v37, v38) (Fig. 2). These ﬁndingsjustiﬁed the need to edit the existingGLI2 exon/intron structure nomen-
clature. According to our revision,GLI2 gene spans at least twenty exons,
four of which are in the 5′ non-coding area and sixteen are in the coding
region (Fig. 2B).
To identify the correct transcription start and termination sites, 5′
and 3′ rapid ampliﬁcation of cDNA ends (5′ and 3′ RACE) analyses of
human GLI2 were performed using fetal brain and LoVo colon cancer
cell samples. Four alternative transcription start sites (TSSs), one in
exon II, two in exon III, and one in exon XI, were identiﬁed (Fig. 2B).
The TSS in exon I coincided with the one described by Kimura and
colleagues [29], whereas we did not detect any TSS upstream of exon
IV, although transcripts initiating from exon IV have been described by
Dennler [15]. From 3′ RACE analysis data we found a novel internal al-
ternative polyadenylation site downstream of exon XV (v40–v41;
Fig. 2C). These data indicated that GLI2 is extensively regulated by tran-
scriptional start and termination site selection.
Consequently, we took a closer look at the expression of transcripts
with TSSs in exons I–III andwith the alternative termination site in exon
XV by using RT-PCR analysis and transcript-speciﬁc primers. Complex
patterns of GLI2 splice variant expression with differential proﬁles
across normal tissues and in cancer were observed (Fig. 1B). It was con-
cluded that exons I, II and III are used in a mutually exclusive manner
(Fig. 2C; v21–v38) with predominant expression of transcripts starting
at exon II (Fig. 1B). In general, alternative splicing affected the 5′ exon
usage of GLI2 more in cancer and fetal tissues as compared to adult
(Fig. 1B). In contrast, the abundance of GLI2mRNAs with the novel 3′
UTRs was high in adult tissues and cancer, but comparatively low in
fetal tissues (Fig. 1B).
In conclusion, ﬁndings of the complexity of alternative transcription
and termination site usage suggested that transcriptional regulation
along with RNA processing might be the key processes determining
the tissue-speciﬁc activities of GLI2.
3.2. Promoter upstream of exon XI is highly active in metastatic melanoma
cells
Identiﬁcation of several novel TSSs of GLI2 suggested that multiple
alternative promoters regulate the transcription of the gene. To exam-
ine the relative strengths of GLI2 promoters, we used a reporter gene
assay and analyzed the promoter activity of regions preceding exons I
(P1) (TSS described by Kimura et al. [29]), II (P2), III (P3) and XI (P4)
of GLI2 (novel TSSs identiﬁed by 5′ RACE analysis) (Fig. 3A) in different
cancer cells (glioma U373, breast cancer MDA-MB 231, melanoma
WM266-4, SkMel-28 and A375M cells, Fig. 3B). All regions exhibited
distinct transcription promoting activities across cells analyzed
(Fig. 3B). Speciﬁcally, the activity of promoters P2 and P4 preceding
exons II and XI, respectively, was remarkably higher in melanoma
cells, whereas the activity of promoters P1 and P3, located upstream
of exons I and III respectively, was relatively weaker (except for the
high activity of promoter P1 in melanoma A375M cells, Fig. 3B). The ac-
tivity of promoter P4 governs the synthesis of mRNAs that encode the
major activator isoforms of GLI2 with no N-terminal repressor domain
and a molecular weight of 133 kDa. Thus our data concluded that GLI2
expression is controlled by at least four alternative promoters. In addi-
tionwe found that P4 that precedes exonXI and gives rise toGLI2ΔNac-
tivator isoforms is highly active in melanoma cells.
The fact that promoter P1 exhibited exceptionally high activity only
inmelanoma A375M cells provoked us to examine the usage of alterna-
tive promoters coupled with internal transcriptional termination in
different melanoma cells (Fig. 3C). Indeed, RT-PCR analysis with
transcript-speciﬁc primers revealed, that transcripts initiated at exon I
and terminated at exon XV* were highly expressed in melanoma
A375M cells (Fig. 3D), whereas those with exon II were common to all
melanomas, and transcripts starting with exons III and IV [15] were
not detected in any of the cells analyzed (Fig. 3D). Thus, the transcrip-
tional regulation of GLI2 yielding GLI2ΔC isoforms with a molecular
Fig. 1. Expression of alternative splice variants (ASVs) ofGLI2 in different cancer cells andhuman tissues. A.GLI2 transcripts aremore abundant in cancer cells and fetal tissues than in adult.
Cell- and tissue-speciﬁc expression of human GLI2 coding region was analyzed using primer pairs spanning exons V to XVI (see NCBI gene nomenclature on Fig. 2A, see primer sequences
and positions in Supplementary Table S1 and Supplementary Fig. S1). For primary cells, we used commercial RNA extracted from colon carcinoma (clinical stages I–IV and tumor grades
1–3, age range 25–83 years, BioChain Institute, Inc.), breast carcinoma (clinical stages I–IV and tumor grades 1–3, age range 25–83 years; BioChain Institute, Inc.) andmelanoma (age range
42–83 years; BioChain Institute, Inc.). Cancer cell lines and tissues that were studied in more detail, included: 1. CoLo (colon cancer), 2. LoVo (colon cancer), 3. MCF-7 (breast cancer), 4.
Hs578T (breast cancer), 5. SkMel-28 (melanoma), 6.WM266-4 (melanoma), 7. 1321N1 (astrocytoma), 8. U373 (glioblastoma-astrocytoma), 9. fetal brain, 10. fetal colon, 11. fetal skin, 12.
adult brain/cerebellum, 13. adult brain/corpus callosum, 14. adult brain/hippocampus, 15. breast, 16. colon, 17. heart, and 18. testis. NC— normal colon, NB— normal breast, NM— normal
melanocytes, NTC— negative control, cDNA omitted from PCR reaction. Analysis of GAPDHmRNA expression levels was performed to normalize the differences in the amounts of mRNA
across samples. FL (full length) indicates the full length GLI2mRNA (NM_005270.4), v_# indicate corresponding splice variants (see Fig. 2B). B. Expression analysis of GLI2mRNAs with
alternative 5′ and 3′ UTRs in cancer cells and fetal and adult tissues. Cell- and tissue-speciﬁc expression of human GLI2 5′ non-coding region was analyzed using primer pairs spanning
across exons I and VIII, exons II and VIII and exon IIIs and VIII according to edited nomenclature. To study the expression of transcripts with newly described termination sequences, a
primer pair encompassing exons XII to XV extended (XV*) was used (see Table S1 and Fig. S1). 1. CoLo (colon cancer), 2. LoVo (colon cancer), 3. MCF-7 (breast cancer), 4. Hs578T (breast
cancer), 5. SkMel-28 (melanoma), 6. WM266-4 (melanoma), 7. 1321N1 (astrocytoma), 8. U373 (glioblastoma-astrocytoma), 9. fetal brain, 10. fetal colon, 11. fetal skin, 12. adult brain/
cerebellum, 13. adult brain/corpus callosum, 14. adult brain/hippocampus, 15. breast, 16. colon, 17. heart, and 18. testis, NTC— negative control, cDNA omitted from PCR reaction. Analysis
of GAPDHmRNA expression was performed to normalize the differences in the amounts of mRNA across samples. v_# indicate corresponding splice variants (see Fig. 2C).
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two alternative promoters, P1 and P2.
Altogether, these data suggested that differential regulation of
GLI2 expression is critical for cancer phenotype. Therefore we exam-
ined the expression patterns of known melanoma-speciﬁc GLI2 tar-
get genes in different melanoma cells. As illustrated in Fig. 3E, the
patterns of ZEB1, SNAI1, CDH1, MITF-M, TYR and TYRP1 expression
were highly melanoma cell speciﬁc. More precisely, expression of
ZEB1, that promotes melanoma invasiveness [7] and is a direct target
of GLI2 and SNAI1, was signiﬁcantly (p b 0.05 or p b 0.005) higher in
A375M cells as comparedwith SkMel-28 andWM266-4 cells. In con-
trast, expression of CDH1 and MITF-M, that are characteristic
markers of a less invasive and more proliferative melanoma pheno-
type [7,8], was relatively lower (p b 0.05 or p b 0.005) in A375M cells.
The expression of MITF-M-associated genes TYR and TYRP1 was also
notably weaker in A375M cells as compared with SkMel-28 and
WM266-4 cells (Fig. 3E). These data were in good agreement withearlier studies reporting the role of GLI2 in generation of melanoma
heterogeneity [6].
In conclusion, these results indicated that increased expression of
transcripts encoding GLI2ΔN and GLI2ΔC isoforms correlates with
high expression of GLI2 target genes that induce metastatic phenotype
of melanoma.
3.3. GLI2ΔN and GLI2ΔC protein isoforms have parted activator and
repressor domains
The fact that promoters P1 and P4 exhibited exceptionally high ac-
tivity in melanoma A375M cells provoked us to further examine the
regulation of GLI2 in those cells. Transcripts encoding GLI2ΔN initiated
from P4 preceding exon IX are about 900 nucleotides shorter in their
5′ but otherwise similar to transcripts encoding canonical GLI2. There-
fore, we performed ribonuclease protection assay (RPA) to speciﬁcally
examine the relative levels of expression of transcripts encoding
Fig. 2.Genomic organization of GLI2 locus, alternative splicing patterns and structural domains of GLI2. A. A schematic representation of the human GLI2 protein. Numbers below indicate
amino acid positions. Functional domains, nuclear localization signal (NLS) and potential binding sites for regulatory proteins (SUFU, CBP/p300, TAF
II
31) are shown, diagonally striped box
represents the area of phosphorylation sites for PKA,GSK3-beta and CKI, square-ﬁlled area shows thedegron that directs the starting place of degradation [2,9,11]. Genomic organization of
GLI2 under the scheme of the protein structure is presented according to theNCBI assembly GRCh38.p2 (NG_009030.1). Boxes indicate exons and are drawn to scale, lines indicate introns.
The numbers above indicate the sizes of introns. Position of the canonical translation start-site [37] is shown. Romannumbers represent exon numbers. B. Revised genomic organization of
GLI2 andmajor ASVs. Boxeswith Roman numbers above the structure indicate exons and are drawn to scale, lines indicate introns. Red boxes indicate novel exons or exon extensions. The
numbers above and below the gene structure indicate the sizes of introns and exons, respectively. Positions of alternative translation start-sites [37] are shownbyvertical arrows above the
structure.Oriented arrowsbelow indicate thepositions of transcription start-sites. Filledboxes indicate the coding region ofmRNAs,white boxes represent thenon-coding regions. Dashed
lines and asterisks (*) indicate alternative donor or acceptor splice-sites. v1–v5 are previously known splice variants from NCBI assembly Feb. 2009 (GRCh37/hg19). v6–v19mRNAs are
newly identiﬁed splice variants of GLI2 gene. Major protein domains (Repressor, Zn-ﬁnger and Activation) of GLI2 are colored in three different colors and corresponding domains are
shown for mRNAs. C. Novel alternative transcripts of GLI2 with newly identiﬁed non-coding ﬁrst exons (v21–v39) and exon IX extension (v40, v41). Boxes with Roman numbers above
indicate exons and are drawn to scale, lines indicate introns. Filled boxes indicate the coding region of mRNA, white boxes represent the non-coding region. Asterisks (*) indicate alter-
native donor or acceptor splice-sites.
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GLI2ΔN was detected by RNA probe 1 spanning exons X to XII
(Fig. 4A) generating hybridization products corresponding to the full
length GLI2 (360 bp) and alternative transcripts of GLI2 with TSSs in
exon XI (231 bp) (Fig. 4B). Expression of mRNAs encoding GLI2ΔC
was detectedwith the RNA probe 2 spanning exons XIII to XV extension
(marked as XV*) (Fig. 4A) producing full length hybridization products
(222 bp) and alternative mRNAs with a termination site in exon XV*
(401 bp) (Fig. 4B). Analysis of the housekeeping gene GAPDH (530 bp)
was used as a control (Fig. 4A–B). These data afﬁrm the endogenous ex-
pression of transcripts coding for GLI2ΔN and GLI2ΔC protein isoforms.
In silico analysis of alternatively spliced GLI2 mRNAs predicted that
most ORFs start with the canonical ATG located in exon V of GLI2,
whereas simultaneous exon VI or VII inclusion leads to the formation
of isoforms GLI2ΔN_47aa (v26, v37) and GLI2ΔN_33aa (v27, v38) contain-
ing a deletion in the N-terminal repressor domain (Fig. 2). Alternative
ATGs located in exons IX and XII produce protein isoformsGLI2ΔN_125aa
(DQ004396) and GLI2ΔN_328aa (AB007295 and AB007296). Isoform
GLI2ΔC_1096aa (v40, v41) with an intact N-terminal repressor domain
is, however, the product generated by usage of the alternative polyA
site in exon XV* (Fig. 2). Since the effects of partial truncation of the re-
pression and activator domains on GLI2 function are unknown, herein
GLI2ΔN_328aa isoforms with no repression domain are referred to as
GLI2ΔN, and GLI2ΔC_1096aa isoforms with no activation domain are re-
ferred to as GLI2ΔC.
It is well established that most of the commercial anti-GLI2 antibod-
ies recognize the canonical GLI2 protein of 166 kDa and its isoformwith
a molecular weight of 133 kDa. To our knowledge, none of the studies
have ever questioned the nature of the 133 kDa isoform. According to
our molecular analysis data this corresponds to the GLI2ΔN isoform
(GLI2ΔN_328aa). Furthermore, the majority of studies on GLI2 function
have used recombinantly produced GLI2ΔN isoforms to analyze the ac-
tivator function of GLI2 [18–20]. Data from Western blot analysis
exploiting three commonly-used anti-GLI2 antibodies revealed the ex-
pression of multiple isoforms of GLI2 with molecular weights ranging
from ~46 kDa to 168 kDa in a cell-speciﬁc manner (Fig. 4C). However,
relative to GLI2ΔN (133 kDa) and GLI2ΔC (48 kDa) isoforms, the levels
of canonical GLI2 protein of 166 kDa were always detected as low
(Fig. 4C). AlthoughGLI2ΔN_47aa andGLI2ΔN_33aa isoformswere not dis-
criminated due to the resolution limitations ofWestern blot analysis,we
detected different C- and N-terminally truncated isoforms of GLI2 with
molecular masses ranging from ~55 kDa to ~120 kDa (Fig. 4C). These
initial data strongly refer to the need for additional proteomic studies
to identify the precise structure of partly truncated isoforms of GLI2.
Comparative protein pattern of GLI2 with marked expression of
GLI2ΔN (133 kDa) and GLI2ΔC (48 kDa) isoforms was also detected in
breast and colon cancer cells (Fig. S2).
These data together with the results from RPA and Western blot
analysis further conﬁrmed that cell-speciﬁc splicing, alternative initia-
tion and termination of GLI2mRNAs results in separating the activator
and repressor functions of GLI2 into discrete proteins, GLI2ΔN and
GLI2ΔC (Fig. 4D).
3.4. Post-transcriptional processing of GLI2 producing GLI2ΔN and GLI2ΔC
isoforms is under the control of TGFbeta1 in invasive melanoma cells
Finally, we examined the relevance of high levels of GLI2 alternative
mRNAs and protein isoforms in metastatic melanoma. Extracellular
matrix-coated polycarbonate ﬁlter migration assay (Fig. 5A) was used
to analyze changes in gene expression upon cell migration. As the tran-
scripts of GLI2ΔN are initiated from P4 preceding exon XI and therefore
shortened at their 5′ ends but otherwise similar to transcripts encoding
canonical GLI2 protein, we used the semi-quantitative RT-PCR analysis
to measure the relative expression of transcripts encompassing exons
encoding the N-terminus, the internal region and the C-terminal
part of GLI2 (Fig. 5B). RT-PCR analysis showed that migrating cellsexpressed high levels of transcripts encodingGLI2ΔC (primers spanning
N-terminal exons V to XI and VIII to XI) and GLI2ΔN (primers spanning
C-terminal exons XV to XIX) protein isoforms and low levels of full-
length GLI2 mRNAs (primers spanning internal exons VIII to XVI and
IX to XVI), as compared with non-migrating cells (Fig. 5B). High expres-
sion of novel isoforms of GLI2 was detected byWestern blot analysis in
migrating cells, namely GLI2ΔN_328aa generated by promoter P4, and
GLI2ΔC_1096aa produced due to internal polyadenylation downstream
of exon XV, as compared with non-migrating melanoma cells (Fig. 5C).
Furthermore, expression of melanoma-speciﬁc target genes of GLI2, in-
cluding CDH1,MITF-M, ZEB1 and SNAI1 was characteristic to migrating
cells with a metastatic phenotype (Fig. 5D). Speciﬁcally, it was detected
that ZEB1 and SNAI1 are expressed in an opposite pattern to CDH1 and
MITF-M (p b 0.05 or p b 0.005). To summarize, these data demonstrate
that transcription and RNA processing are the key mechanisms driving
the expression of GLI2 isoforms with activator function leading to pro-
motion of invasiveness and metastatic character of cancer cells.
Given that GLI2 is a direct transcriptional target of the TGFbeta1/
SMAD pathway [14,15], it was interesting to reveal whether the regula-
tion of alternative splicing of GLI2 is under the control of TGFbeta1 sig-
naling. TGFbeta1 enhanced the expression of all GLI2 mRNAs in
melanoma A375M cells including those encoding GLI2ΔN and GLI2ΔC
(Fig. 5B–C). These data are in harmonywith previous ﬁndings reporting
that autocrine TGFbeta1 activity controls GLI2 expression in melanoma
cells [6]. Upon migration both TGFbeta1 treated and untreated melano-
ma cells predominantly expressed transcripts encoding GLI2ΔN and
GLI2ΔC (Fig. 5B). Consistently, expression of GLI2 target genes contrib-
uting to migratory phenotype was further enhanced upon TGFbeta1
treatments (Fig. 5D). This supports our previous ﬁndings that expres-
sion of GLI2 target genes is strongly affected in cells expressing high
levels of GLI2 isoforms with activator functions.
Presented data enable us to conclude that invasive melanoma cells
express predominantly GLI2ΔN and GLI2ΔC isoforms under the control
of TGFbeta1.
4. Discussion
Analysis of the mechanisms underlying cell-speciﬁc activity of GLI2
led us to conclude that: i) the function of GLI2 as a transcriptional acti-
vator is controlled at the level of differential promoter usage, alternative
splicing and selective initiation and termination of transcription, and ii)
isoforms (GLI2ΔN and GLI2ΔC) with transcription activator activity are
generated due to the selective and signal-enhanced control of transcrip-
tion and RNA processing, whereas these isoforms drive the invasive and
metastatic potential of melanoma cells.
GLI2 is known for its dual role in the regulation of transcription as it
contains an N-terminal repression and a C-terminal activation domain
[9]. Despite 15 years of studies, understanding of themolecular mecha-
nisms that govern the formation of activator isoforms of GLI2 has
remained vague. Early works by Pan and colleagues [30–32] demon-
strated that GLI2 activity is controlled by post-translational proteolytic
processing that generates truncated GLI2 isoforms with solely a repres-
sor function. Since proteolysis of GLI2 is a highly inefﬁcient process [32,
33], it apparently cannot be the only mechanism for the regulation of
GLI2 activity. Most recent studies have found canonical GLI2 to be a
weak activator, whereas removal of the N-terminal repressor domain
is required for the full exposure of its power as a transcriptional activa-
tor [9,17–19]. However, until this study, there has been no molecular
understanding of the mechanisms responsible for the generation of
GLI2 activator proteins.
Our data show that combinatorial uses of alternative initiation, splic-
ing and termination are the key mechanisms that control the activity of
GLI2.We have identiﬁedmultiple alternatively spliced GLI2mRNAs that
are expressed at high levels both in normal tissues and in cancer. Be-
cause of these ﬁndings we were obligated to assign a new exon/intron
nomenclature for GLI2 that provides a better clarity for future studies
Fig. 3. Promoter upstream of exon XI is highly active in metastatic melanoma cells. A. Schematic representation of GLI2-luc reporter constructs used in this study. The locations of the
transcription start sites are indicated. B. Multiple promoters of GLI2 show high activity in A375M melanoma cells. GLI2 promoter regions were analyzed by luciferase assay in U373,
MDA-MB 231, SkMel-28, WM266-4 and A375M cancer cells. The relative activity of the luciferase reporter is normalized to that of pGL3-luc-egfp vector. The activity values were further
corrected to the Renilla luciferase activity, which served as the internal reference for the transfection efﬁciency. Data shown aremean± SD of three independent experiments. C. A sche-
matic representation of alternative mRNAs encoding GLI2ΔC protein isoforms. Position of the translation start-site [37] is shown by a vertical arrow above the mRNA structure. Oriented
arrows below indicate the positions of transcription start-sites. Filled boxes indicate the coding regions of mRNA, white boxes represent the non-coding regions. Protein domains are col-
ored and correspond to domains shown in Fig. 2. D. RT-PCRanalysis of alternative transcripts ofGLI2with exon I revealedmelanoma-speciﬁc expression of thesemRNAs. Expression ofGLI2
transcripts encoding Gli2ΔCwas analyzed using primer pairs spanning exons I/II to extended exon XV(*) or XVI (see primer sequences and positions in supplementary Table S1 and sup-
plementary Fig. S1, respectively) inWM266-4, SkMel-28 and A375Mmelanoma cells. E.Melanoma cells show differential patterns of expression ofGLI2 target genes. Quantitative analysis
of expression of GLI2 target genes (ZEB1, SNAI1, CDH1,MITF-M, TYR, TYRP1, primers in Table S1) was carried out inWM266-4, SkMel-28 and A375Mmelanoma cells. All results were nor-
malized to expression of RPLP0. Data shown aremean± SD of three independent experiments. Statistical signiﬁcance is indicated by p-values (Student's t test; *— p b 0.05, **— p b 0.005,
*** — p b 0.001).
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is initiated from several mutually exclusive promoters that precede dif-
ferent 5′ upstream and internal exons. For example, the high activity of
promoter P2 preceding exon II is common to most cells, in contrast to
cell-speciﬁc activity of promoters P1 and P4 preceding exons I and XI.
In melanoma A375M cells with metastatic characters, the increased
production of GLI2ΔC is driven by promoters upstream of exons I and
II (P1 and P2), whereas in less malignant cells only promoter P2 is
active.Furthermore, transcripts initiated from promoter P4 with a TSS in
exon XI provide the ﬁrst evidence of a mechanism for the formation of
the 133 kDa GLI2ΔN isoforms with no repressor domain. In 1998,
Tanimura and colleagues identiﬁed the cDNA encoding GLI2-α that re-
sembles GLI2ΔN in its amino acid sequence [16]. This putative transcript
starts at exon IV and is lacking exonsVI–XI.We could not detect theGLI2
transcripts described by Tanimura and colleagues [16] in any of the tis-
sues or cells studied. Given that there are no further data of mRNAs
encoding GLI2-α isoforms, these transcripts are extremely rare and
Fig. 4.MelanomaA375Mcells express high levels ofGLI2 isoforms acting as transcription activators. A. A schematic representation of cDNAprobes used for RPA. Probe1 spanning exons X–
XII of GLI2; probe 2 spanning exons XIII–XV* of GLI2; probe 3 is GAPDH speciﬁc. B. Expression of transcripts encoding GLI2ΔN and GLI2ΔC proteins was high in melanoma A375M cells as
conﬁrmed by RNAse protection assay. Exon structure corresponding to the protected RNA fragments is shown on the right: transcripts with the size 360 bp and 231 bp are designated as
exonX-XII (FL) and exons XI–XIII (alternative transcripts ofGLI2with TSSs in exon XI), or 222 bp as exons XIII–XV* (alternativemRNAswith a termination sites in exonXV*) and 401 bp as
exons XIII–XV (FL). RNase H treated (Yeast) and untreated yeast RNA (Probe) were used as RPA assay controls. C. Melanoma A375M cells express different isoforms of GLI2, whereas
predominantly GLI2ΔC and GLI2ΔN as evidenced by Western blotting analysis. For analysis, the following primary antibodies were used: Santa Cruz Biotechnology sc-20291 anti-GLI2
(epitope in the internal region of GLI2), Santa Cruz Biotechnology sc-20291 anti-GLI2 (epitope in the C-terminus of GLI2), and R&D Systems AF3635 anti-GLI2 (epitope in N-terminus
of GLI2). Position of the protein molecular weight marker (in kDa) is indicated on the right. Expression of Lamin B1 was analyzed for normalizing purposes. D. GLI2ΔC and GLI2ΔN are
the predominant activator forms of GLI2 protein isoforms in cells. Schematic representation of the relatedness of GLI2 protein isoforms to the corresponding genomic regions. Numbers
below the structure of the canonical protein indicate amino acid positions. Functional domains and potential binding sites for regulatory proteins (SUFU, CBP/p300, TAFII31) are shown,
diagonal lines represent the area of PKA, GSK3-beta and CKI phosphorylation sites [2,9,11]. Boxes indicate exons and are drawn to scale, lines indicate introns. Positions of alternative trans-
lation start-sites [37] are shown by vertical arrows above the structure. Oriented arrows below indicate the alternative transcription initiation sites, dashed lines indicate translation stop
codons. Numbers below the protein structure indicate amino acid positions. Protein domains (Repression, Zn-ﬁnger and Activation) are colored (see Fig. 2A). Novel exons characterized by
this study are shown in red.
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study is the ﬁrst to show that GLI2ΔN isoforms are generated from pro-
moter P4 upstreamof exon IX that iswidely used in different tissues and
cell types. The extensive use of promoter P4 supports promoter-coupled
alternative splicing as themajor mechanism for generation of GLI2 pro-
teins with an activator domain only (133 kDa GLI2ΔN isoforms). Addi-
tionally, we show that the use of the internal polyadenylation site
downstream of exon XV results in GLI2ΔC isoforms with no activator
domain and disrupted DNA-binding surfaces. Given that GLI2ΔC iso-
forms are unlikely to bind DNA due to the absence of zinc ﬁngers 3 to
5, they can compete for the interaction with cellular factors targeting
the repressor-domain. Furthermore, as isoformGLI2ΔC retains the bind-
ing site for Suppressor of fused (SUFU), in most probably counteracts
SUFU's activity as a negative regulator of Hh signaling [34,35]. Consis-
tent with this suggestion, earlier overexpression studies with plasmids
harboring the repressor domain of GLI2 (encoded by exons VII–XII)
demonstrated that these GLI2ΔC-like proteins acted as transcriptional
activators in the presence of canonical GLI2 [9]. These data allow us to
conclude that GLI2ΔC functions largely as a transcriptional activator
enhancing the activator activity of GLI2. Altogether, our results show
for the ﬁrst time that regulation of GLI2 transcription supported byalternative splicing allocates the transcriptionally important activator
and repressor domains of GLI2 into different isoforms of GLI2ΔN and
GLI2ΔC (see Fig. 4D).
We observed that highlymetastatic melanoma cells which express a
plethora of GLI2 target genes (ZEB1, SNAI1, CDH1, TYR, TYRP1 andMITF)
supporting melanoma cell invasion have distinct patterns of transcrip-
tional regulation of GLI2. We found that migrating cells expressed high
levels of transcripts encoding GLI2ΔN and GLI2ΔC, whereas full-length
GLI2 mRNAs and canonical forms of GLI2 were barely detectable.
Along with this, the expression of two important metastatic inducers
downstream of GLI2, ZEB1 and SNAI1 [7], was exclusive to invasive cell
population. Based on the results of the current study we propose that
signal-induced regulatory mechanisms at the level of transcription
and post-transcriptional processing contribute to the cancer-speciﬁc ac-
tivity of GLI2. Recent studies with ectopic expression of recombinant
GLI2ΔN have reported induced mesenchymal transition of melanoma
cells with enhanced expression of E-cadherin andMITF-M [7] and geno-
mic instability of human epithelial cells [19] are in good correlationwith
our ﬁndings. Our study established that expression of GLI2 transcripts
encoding isoforms with an activator function is under the control of
TGFbeta1. Earlier ﬁndings have reported both Hh-dependent as well
Fig. 5. The effects ofmigration and TGFβ1 treatment on the expression of GLI2 isoforms andGLI2 target genes inA375Mmelanoma cells. A.Microscopypictures of trypanblue stainedmigrated
A375M cells on polycarbonate membranes in the presence (+) or absence (−) FBS as a chemoattractant are shown. FBS is used as an effective chemoattractant for melanoma cell migration
stimulation. Graphwith the normalized data of OD values of absorption reﬂecting the number ofmigrated A375Mmelanoma cells in response to fetal bovine serum (FBS) is shown on the left.
Data aremean±SDof three independent experiments. B. RT-PCR analysis of GLI2 expression inmigrated (+) and non-migrated (−) and TGFβ1 treated (+) and non-treated (−) A375M cell
populations. Analysis of 5′, internal and 3′ regions of GLI2 transcripts indicate that migrated cells express predominantly transcripts encoding GLI2ΔC and GLI2ΔN upon migration and in re-
sponse to TGFβ1 treatment. FL, v_# (left) indicate corresponding splice variants (see Fig. 2B). Analyzed exons are provided on the right (see primer sequences and positions in supplementary
Table S1 and supplementary Fig. S1, respectively). Neg— negative control, cDNA omitted from PCR reaction. Analysis of GAPDHmRNA expression levels (below) was performed to normalize
the differences in the amount ofmRNA across samples. C. Migrated and TGFβ1 treated cells express high levels of GLI2ΔC and GLI2ΔNproteins.Western blotting analysis of GLI2 expression in
migrated (+), TGFβ1 treated andnon-manipulated (Control) A375Mcells. ExpressionofGAPDHwas analyzed for normalizingpurposes. Data of quantiﬁcation ofWestern blot results is shown
on graphs in the right. Results were normalized to the non-migrating/untreated control sample, the relative values of which are represented as dashed line and adjusted to 1. Error bars rep-
resent standard deviation. Standard deviationswere calculated frommultiple independent quantiﬁcations of a single blot. Used antibodies: Santa Cruz Biotechnology sc-20291 anti-GLI2, R&D
Systems AF3635 anti-GLI2, and Sigma G8795 anti-GAPDH. D. TGFβ1 and cellular migration have similar effects on the expression of GLI2 target genes by supporting motility and invasion.
Quantitative expression analysis of GLI2 target genes (MITF-M, CDH1, ZEB1, SNAI1, primers in Table S1) in migrated (left graph) or TGFβ1 treated (right graph) A375M cells. All results were
normalized to the expression of RPLP0. Data shown are mean± SD of three independent experiments. Dashed line represents the relative levels of gene expression in non-migrated and un-
treated cells adjusted to 1.
54 H. Sadam et al. / Biochimica et Biophysica Acta 1862 (2016) 46–55as Hh-independent regulation of GLI activation consequently contribut-
ing to tumor progression via acting upon cell cycle, apoptosis and devel-
opment of metastasis [2–4,20,36]. Regarding TGFbeta1, earlier studies
have found this signal-induced mechanism of GLI2 as a key in con-
trolling phenotypic plasticity and invasive behavior of melanoma
cells [5,6]. All these data are in good agreement with ours, whereas
our ﬁndings establish the critical role of RNA processing of GLI2
that is essential not only its cell-speciﬁc activities but also governing
cancer (melanoma) progression and invasion.
In conclusion, given that the number of studies on GLI2 function in
development and cancer development is increasing, our data emphasize
the key role of RNA splicing and processing in controlling the formation
of active forms of GLI2 and that targeting of speciﬁc alternative splicingevents can serve as ﬁne-tuner in important and complex cellular
functions of GLI2.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.10.008.
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